01About This Special Issue
The aim of this special issue titled " Immunotherapy" is to enhance effective health care delivery by giving researchers opportunity to share their recent findings in the stimulation of immune system .Immunotherapy is the "treatment of disease by inducing, enhancing, or suppressing an immune response". Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapy
The active agents of immunotherapy are collectively called immunomodulators. They are diverse array of recombinants, synthetic and natural preparations, often cytokines. Some of these substances, such as granulocyte colony-stimulating factor, interferon, imiquimod and cellular membrane fractions from bacteria are already licensed for use in patens. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine oligodeoxynucleotides and glucans are currently been investigated in clinical and preclinical studies.
Immunomodulatory regimes offer an attractive approach as they often have fewer side effects than the existing drugs, including less potential for creating resistance in microbial disease. Immune effector cells such as lymphocytes, macrophages dendritic cells, natural killer cells, cytotoxic T lymphocytes work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of the tumor due to mutation.
For this special issue; researchers are encouraged to send in their manuscripts covering the following topics:
1. Autologous immune enhancement therapies
2. Vaccination
3. Cancer immunotherapy
4. Immunosuppressive drugs
5. Allergen immunotherapy
6. Helminthic therapies
7. Genetically engineered T cells
8. T cell adoptive transfer
9. Dendritic cell-based immunotherapy
02Meet the Guest Editors
Our distinguished editors bring deep subject-matter expertise to curate high-quality research and ensure a rigorous peer-review process.
Lead Guest Editor
Julius Oloke
Department of Microbiology and Immunology, All Saint University, St. Vincent and the Grenadines
Guest Editor
Sunny Kumar
University of California Santa Barbara (UCSB), Santa Barbara, CA, United States
Guest Editor
Preety Sahdev
Allergan Inc, Pharmaceutical Sciences, Irvine, United States
03Published Articles
The following articles have been published in this special issue.
-
Issue: Volume 3, Issue 2-1, March 2015Pages: 8-20Received: 14 January 2015Accepted: 19 January 2015Published: 7 February 2015Abstract: In the recent years, mushrooms are distinguished as important natural resources of immunotherapy which can be used as immunomodulating and immunostimulating in the management of some immunodeficiency diseases such as cancer, tumour, HIV, tuberculosis etc. Mushroom of the genus Pleurotus are good sources of several bioactive compounds which are able... Show More -
Challenges of the Control of Opportunistic Infections of Zoonotic Origin in HIV/AIDS Patients
Issue: Volume 3, Issue 2-1, March 2015Pages: 1-7Received: 14 January 2015Accepted: 19 January 2015Published: 7 February 2015Abstract: The HIV/AIDS pandemic is associated with a number of opportunistic infections of immunocompromised person. Some of these infections are recognized zoonoses that are naturally transmitted between animals and humans. These may be directly transmitted by, animals or indirectly by contact with contaminated food and water. Interactions between animals a... Show More
